SARC044: NOW RECRUITING FOR PATIENTS

Research
Catalyzing Scientific and Clinical Progress
Active Clinical Trials

Completed Clinical Trials

Publications

Funding Opportunities

Career Development Award

Catalyst Program

Biospecimen Bank

Clinical Data Repository

Imaging Resources

Submit a Concept

Trial Design

Tumor Board
Patient Resources
Resources for Patients, Families, and Caregivers
Find a Sarcoma Center

SARC Talk Podcast

Find a Clinical Trial

Patient Advocacy Directory

What is sarcoma?

Soft Tissue Sarcoma Reference Guide

Bone Sarcoma Types
Meetings
Collaborating to Cure Sarcoma
SARC Meeting Before ASCO

SARC Meeting As Part of CTOS

Past Meetings

SASS Conference
About SARC
Together We Can Change Patient Outcomes
Impact

Team

News

Newsletter

History

Financials
Partner With Us
Investing in the Future of Sarcoma Research
For Donors & Supporters

For Industry

For Patients & Caregivers

For Researchers & Clinicians

Sign Up For News
Contact Us
Donate

Search

Home » Team » Nathan Webster

Nathan Webster, APRN FNP

Nathan Webster

Director, US Oncology Clinical Education at Daiichi Sankyo, Inc.

Share:

Join OUR community

Stay up-to-date on clinical trials and learn from our team of sarcoma experts.

About Sarc

SARC (Sarcoma Alliance for Research through Collaboration) is a U.S.-based 501 (c)(3) non-profit cancer research organization dedicated to the development and support of research for the prevention, treatment, and cure of sarcoma – a cancer of the bone and connective tissues of the body.

P.O. Box 406 | Ann Arbor, MI 48106
Phone: 734.930.7600 | Fax: 734.930.7557 | Email: sarc@sarctrials.org

Financial Conflict of Interest Policy

For:
DONORS & SUPPORTERS
INDUSTRY
PATIENTS & CAREGIVERS
RESEARCHERS & CLINICIANS

© 2025 Sarcoma Alliance For Research Through Collaboration

Stay in touch

We respect your privacy and are committed to protecting the confidentiality of those who use our web site or interact with us online. SARC does not share, sell, or exchange any information about visitors, donors, newsletter recipients, nor our constituents with any third party.